Goldman Sachs on Monday resumed coverage of Puig Brands with a Buy recommendation, setting a price target of €21.50 - a level that suggests around 34% upside from the stock's prevailing price. The firm said the market is underestimating the company’s runway for growth, especially in women’s fragrance, and sees multiple avenues for expansion across the company’s portfolio.
In its analysis, Goldman highlighted the imbalance in Puig’s fragrance business. While the women’s fragrance segment is nearly twice the size of the men’s segment, Puig currently holds only an 8% share of the women’s market compared with a 17% share in men’s fragrances. The analysts, led by Aron Adamski, described the company’s portfolio as "the most skewed in the peer group."
Goldman projects a route for Puig to reach a 9% share in the women’s fragrance segment by 2030. The bank attributes this potential to targeted activity such as Carolina Herrera flanker extensions and a planned Jean Paul Gaultier blockbuster launch expected in the second half of 2026. The analysts emphasize that their assumptions are conservative, noting that the four prestige brands in Goldman’s model would attain less than half of the share gains achieved by the Good Girl fragrance in its first five years.
Beyond perfume, Goldman identifies material growth prospects in makeup and skincare. The Charlotte Tilbury brand already reaches more than 5,000 points of sale worldwide, yet Goldman notes that Europe alone contains roughly 17,000 luxury beauty doors, signaling capacity for further geographic expansion, particularly into Latin America and Asia. In skincare, the bank expects Uriage’s international rollout to contribute meaningfully; Goldman observes Uriage has credentials similar to La Roche-Posay but generates sales that are about eight times smaller, a gap the bank partially attributes to L'Oréal’s broader distribution network.
Puig’s share price performance since its May 2024 initial public offering has been weak, with the stock down roughly 37% from its IPO level. Goldman says this underperformance reflects a multiple reset as fragrance growth normalized and market concerns around Charlotte Tilbury’s makeup trajectory following periods of destocking, a product recall, and pressure from lower-cost lookalike products.
Valuation underpins Goldman’s view of attractive risk/reward: Puig is trading at about 14x calendar-year 2026 price-to-earnings on an assumption of 5% medium-term organic sales growth. The bank argues that as fragrance growth settles, Puig should accelerate its launch cadence, which historically improves sell-in visibility - a dynamic Goldman believes is not fully reflected in the current multiple.
On profitability, Goldman models a modest expansion in adjusted EBITDA margin from 20.7% in fiscal 2025 to 21.1% in fiscal 2028. The firm attributes the improvement to leverage in selling, general and administrative expenses and a normalization in advertising and promotion intensity.
Capital allocation is another element of Goldman’s case. Puig’s relatively low leverage provides room for either share buybacks or acquisitions; the bank incorporates €300 million of buybacks across fiscal 2027-28 in its model. Goldman also notes that recent press reports have linked Puig as a potential bidder for targets such as Dolce & Gabbana, Clarins, and Parfums de Marly.
Overall, Goldman’s reinstatement frames Puig as a company with structural upside tied to an under-penetrated women’s fragrance business, expansion potential in makeup and skincare, a modest margin improvement path, and flexibility in capital deployment.
Summary
Goldman Sachs has reinstated coverage of Puig Brands with a Buy rating and a €21.50 price target, citing a sizable untapped opportunity in women’s fragrance and additional growth levers in makeup and skincare. The bank models a path to 9% share in the women’s fragrance segment by 2030, modest margin expansion through FY28, and €300 million of buybacks across FY27-28.
Key points
- Goldman sets a €21.50 price target on Puig, implying roughly 34% upside from current levels.
- Puig holds 8% share in women’s fragrance versus 17% in men’s - Goldman projects a rise to 9% in women’s by 2030 driven by new launches and extensions.
- Additional growth opportunities exist in makeup (Charlotte Tilbury) and skincare (Uriage), while low leverage leaves room for buybacks or acquisitions.
Risks and uncertainties
- Valuation and growth normalization - Puig has already seen a multiple reset as fragrance growth normalized; a continued slowdown could weigh on the stock (impacts consumer goods and equity markets).
- Operational and product risks - Charlotte Tilbury’s makeup trajectory faced destocking, a product recall, and dupe pressure, which could constrain near-term revenue performance (impacts beauty retail and cosmetics sectors).
- Execution risk on international rollouts and launches - achieving the modeled share gains in women’s fragrance, makeup, and skincare depends on successful product launches and geographic expansion (impacts consumer goods and retail distribution networks).